时间：2023年9月6日
地点：学术会议区W201
邀请全球知名科学家介绍DNA存储、纳米毒理学等前沿科学技术，分享球差电镜、微型化双光子显微镜等高端仪器的研究进展，同时就质谱法和核磁共振法等研究生物大分子结构及功能、新型分离介质制备及蛋白药物、疫苗纯化等最新应用进行探讨和展望。
Paul Westerhoff
教授, 美国亚利桑那州立大学

 
报告题
目：Analytical Strategies to Assess PFAS Removal and Lifecycle Fate during Adsorption or Transformative Water Treatment Processes
报告摘要
Per- and polyfluoroalkyl substances (PFAS) occur in ground and surface water sources across the globe, and proposed drinking water regulations are driving PFAS treatment technology development and implementation. This presentation will first address current treatment technologies, which utilize adsorption (liquid to solid phase transformation), membranes (liquid to liquid separations) or transformative (oxidation or reduction) processes. Examples will be provided how treatment process efficiencies for “real waters” and how the processes challenge analytical methods. Second, the presentation addresses end-of-life for residuals (e.g., activated carbon) that contains PFAS, which will require incineration. Tracking PFAS during incineration requires unique analytical approaches to track fluorinated aqueous, gaseous and solid-phase species. Overall, the presentation will demonstrate how to match PFAS analytical strategies to PFAS drinking water treatment processes. 
个人简介
Dr. Paul Westerhoff is a Regents Professor and Fulton Chair of Environmental Engineering in the School of Sustainable Engineering and the Built Environment at Arizona State University. Since joining ASU he has held various administrative positions. After serving as the Civil and Environmental Engineering Department Chair he was the Founding Director for the School of Sustainable Engineering and the Built Environment, and served later as Associate & Vice Dean of Research in Engineering and ASU Vice Provost for Academic Programming. Dr. Westerhoff is the Deputy Director of a NSF ERC for Nanotechnology Enabled Water Treatment and co-Deputy Director of the NSF STC Science and Technologies for Phosphorus Sustainability Center. His research group addresses questions related to What pollutants exist in the environment? If they occur, do they matter? If they occur and matter, what do we do to address them? with a focus on pollutants in natural and engineered water systems. He has over 400 journal publications (H-index>100) and multiple patents. He is the recipient of the 2020 A.P. Black award, 2019 NWRI Clarke Prize, 2015 ASU Outstanding Doctoral Mentor, 2013 ARCADIS/AEESP Frontier in Research Award, and 2006 Paul L. Busch Award. He was elected to the National Academy of Engineering in 2023.

Paul Breitenbecher
CEO, Breiten Associates LLC


报告题目：False positive, negative, and unexpected Drug Testing Results in the Urine Toxicology Laboratory |药物测试：尿液毒理学实验室使用筛选法（免疫测定法）和确认法（MS）
报告摘要
In 1995 I co-authored a  short article entitled “False-positive Immunoassay Results for Urine Benzodiazepine in Patients Receiving Oxaprozin (Daypro)”. This was published when rapid urine drug screening test methods were first becoming available. The laboratory community was starting to realize that not all assays can be tested for all of the thousands of drugs, substances or endogenous compounds that may potentially cause result errors. 
There are false positive, false negative and unexpected patient urine drug test results that occur in the Urine Toxicology laboratory. 
How does one research these results and assist the clinician in helping to assess these results to treat their patient?
Unexpected urine drug test results can occur during any phase of the testing process; however, the most common usual results occur  during the pre- analytical or patient collection phase. During this phase patients can provide “fake” urine, take substances that can affect the testing method, or they can adulterate/dilute their urine specimen.
Depending on the screening test method used, the test method can be impacted by a variety of substances that can produce either false negative, false positive or usual results. Screening results can also be different than the confirmation results making interpretation of patient results even more confusing.
During this presentation we will review a basic screening test method and confirmation method. And discuss some of these unexpected urine drug test results. 
个人简介
Paul Breitenbecher在罗得岛大学、康涅狄格大学、杜肯大学等高校进修了研究生课程，曾在哈佛先锋医学中心、诺华生物医学研究院、病理实验室公司（Inform Diagnostics，原名Miraca Life Sciences Inc.）等知名医学机构和企业的实验室从事管理工作。现任Breiten Associates LLC公司的首席执行官，为临床实验室和CRO领域的科研人员提供采购、咨询等方面的技术支持。

Robert Wielgosz
国际计量局（BIPM）化学部主任


报告题目：Certified Reference Materials for a Global Greenhouse Gas Monitoring Infrastructure 
报告摘要
Understanding sources and sinks of Greenhouse Gases (GHG) and the impact of policies to mitigate emissions provides a key tool for action against Climate Change. GHG emissions and uptake can be determined through measurement systems that include in situ measurement of GHG concentration at varying levels of spatial distribution. These measurements together with wind-speed measurements and numerical weather prediction and dispersion models can be used to determine spatially and time resolved GHG emissions and sinks. Maintaining a global system of such measurements, as envisaged, for example, by the WMO initiative on a coordinated global Greenhouse Gas Monitoring Infrastructure, requires close attention to quality assurance and equivalence of measurements from different sites.  Significant emissions may lead to small changes in GHG concentration, requiring highly consistent calibration standards at different measurement sites. The presentation will cover the establishment and characterization of CO2 in air standards for the measurements of concentration as well as isotope ratio, for source apportionment, that are required in GHG measurement networks. Generating the highest precision measurements of CO2 in air requires adopting metrological traceability to defined sets of primary standards, the so-called scale approach. The conversion of CO2 in air amount fraction values from one scale to another requires the scale relationships to be well known, noting that the requirement for internal consistency of standards within a scale, such as the WMO-CO2-X2019 scale, is at the 0.01 μmol/mol level, and consistency between different scales should not exceed the 0.02 μmol/mol level [1].  Certified reference materials that are needed to calibrate both in-situ based optical/laser based GHG amount faction and isotope ratio measurements as well as mass spectrometric laboratory-based measurements of isotope ratio will be described, as well as on-going comparisons to verify their equivalence. These comparisons are supporting National
个人简介
Robert Wielgosz博士是位于法国的国际计量局（BIPM）化学部的主任，其气体计量实验室负责组织空气质量和温室气体标准国际比对。这些比对为由国家计量院（NMIs）和指定机构（DIs）组成的世全球大气监测网络提供标准支撑。他是国际计量委员会（CIPM）气候变化和环境领域任务组成员，也是国际计量局-世界气象组织（WMO）“气候行动中的计量”研讨会指导委员会主席。他发表测量科学相关论文60余篇，包括世界气象组织大气气体成分测量指南。他拥有剑桥大学伊曼纽尔学院（英国）的自然科学硕士学位，巴斯大学（英国）的博士学位，并在乌尔姆大学（德国）完成了皇家学会欧洲交流研究。

Oliver J. Schmitz
教授德国杜伊斯堡-埃森大学

报告题目：Development of a New Ionization Source for Single Cell Metabolome Analysis
报告摘要
Although the unrevealing of cellular heterogeneity is limiting for the understanding of complex processes in cancer research as e.g. its influence on the process of metastasising, current research still depends on bulk analysis technologies as no reliable method could be established for real single cell metabolome analysis yet.
The necessary analytical requirements that such a method for single cell metabolome analysis needs in terms of detection limit, sample amount and specificity will be discussed in detail in this presentation. Also, still unsolved problems will be addressed and put up for discussion.
Subsequently, our current work on an ion source, which should be able to destroy the cell and thus release the analytes and ionize them by means of Dielectric Barrier Discharge, will be presented. The current status of developments from the literature and from us will be briefly presented in this talk.
个人简介
In 2009 Oliver J. Schmitz got a full professor in Analytical Chemistry at the University of Wuppertal (BUW). Between 2010 and 2012 he was the chair of the Analytical Chemistry department at BUW. Since 2013, Schmitz has been a full professor at the University of Duisburg-Essen and heads the Institute for Applied Analytical Chemistry.
2009 he cofounded the company iGenTraX UG which develops new ion sources and units to couple separation techniques with mass spectrometers. In 2011 he was one of the founding directorsof the Interdisciplinary Centre for Pure and Applied Mass Spectrometry, University of Wuppertal. Since 2013, Schmitz is also one of the chairmen of the analytica conferences in China and Vietnam and in 2018, together with Agilent Technologies, he founded the Teaching and Research Center for Separation (TRC).
The research fields of Prof. Schmitz are the development of ion sources, use and optimization of multi-dimensional LC and GC, ion mobility-mass spectrometry and coupling analytical techniques with mass spectrometers. Furthermore, he is working about origin of life and metabolomics. Prof. Schmitz was awarded the scholar-in-training award of the American Association for Cancer Research in 2003, the Gerhard-Hesse Prize for chromatography in 2013 and in the same year the Fresenius Lecturer. 2018 he was awarded with the Waksmundzki Medal Award for Analytical Chemistry of the Polish Academy of Sciences. 
   
马光辉
中国科学院院士
美国医学与生物工程院（AIMBE）fellow
中国科学院过程工程研究所研究员
生化工程国家重点实验室主任
中国颗粒学会副理事长
中国化学会会士
中国化工学会会士
中国微米纳米技术学会会士
中国化工学会生物化工专业委员会副主任委员
中国生物工程学会生物基材料专业委员会主任委员


报告题目：新型分离介质的制备和蛋白药/疫苗纯化应用Preparation of Novel Microspheres for Protein / Vaccine Separation Application
Polysaccharide particles such like agarose particles have been widely used in protein separation and purification as chromatographic packing materials by biological scientists and in industry. However, the limitation of conventional agarose particles is that the separation resolution is limited due to their broad size distribution. Furthermore, the particles with large size are usually used for industrial separation and purification to avoid the increase of back-pressure, which also limit the separation resolution. On the other hand, the particulate vaccine such like virus-like particle (VLP) has attracted more and more attention, conventional agarose particles with small pore size not only limited the adsorption of VLP, but also enhanced the disassociation of VLP, resulting very low activity recovery of VLP.We have developed a novel membrane process to prepare uniform agarose particle. By this technique we can control the CV (coefficient of variation) value which representing the size distribution around 15%, and we can prepare small uniform particles with high agarose concentration. Therefore, we can use small particles instead of large particles, and increase the separation resolution and flow rate of chromatography.  We have developed a new process to prepare giga-porous particle with pore size controllable between 100nm to 500 nm, and we found that it not only increased the loading amount of VLP, but also avoided the disassociation of VLP. This was because large pore size weakened the multi-site interaction between VLP and pore. This novel particle has been used for production of particulate vaccine instead of ultra-high speed centrifugation technique, much higher recovery was achieved.
个人简介
马光辉，中国科学院院士，美国医学与生物工程院（AIMBE）fellow，生化工程国家重点实验室主任。国家杰出青年获得者，基金委创新群体首席，中国颗粒学会副理事长，中国化学会会士、中国化工学会会士、中国微米纳米技术学会会士、中国化工学会生物化工专业委员会副主任委员、中国生物工程学会生物基材料专业委员会主任委员。研究方向为均一生物微球和微囊的制备及其在生化工程和医学工程中的应用，研究和开发用于生化分离、药物载体、免疫佐剂（疫苗递送系统）、细胞培养微载体、酶固定化载体等创新产品。在Nat. Mater., Sci. Transl. Med., Nat. Nanotechnol., Nat. Biomed. Eng., Sci. Adv., Nat. Commun., JACS, Adv. Mater.等国际著名学术期刊上发表SCI论文500余篇。出版中英文专著12部，撰写学术书章节22篇。中国发明专利授权81项，国际专利授权12项，专利技术和产品在国内外500多家单位得到应用。获国家技术发明二等奖、北京市科学技术一等奖、中国化工学会科学技术奖基础研究成果奖一等奖、中国颗粒学会自然科学奖一等奖、中国石油和化学工业联合会技术发明一等奖、侯德榜化工科技创新奖、“中国科协全国优秀科技工作者”称号。

程和平
中国科学院 院士
北京大学未来技术学院 教授
北京大学分子医学南京转化研究院 院长
北京大学国家生物医学成像科学中心 主任
国家十三五重大科技设施“多模态跨尺度生物医学成像设施” 首席科学家


报告题目：科技铸器，开启脑科学研究新范式
脑科学研究包括“读、释、写、仿”四个方面，是一门高度交叉的新兴前沿学科。为开发“读、释、写、仿”工具，团队于2017年成功研发了2.2克微型化双光子显微镜，实现了在自由行为小鼠观察大脑神经元活动，开启脑科学研究的新范式。2021年，第二代微型化双光子显微镜问世，实现了三维空间中近千个神经元的功能成像，开启了在自由行为动物研究大脑神经元结构和功能的新范式。2023年成功研发了2.17克的微型化三光子显微镜，首次实现对自由行为中小鼠的大脑全皮层和海马神经元功能成像，为揭示大脑深部神经机制提供了又一利器。为支撑中国的“脑计划”，我们建设了“南京脑观象台”，由相关领域专家领衔，正在开展脑科学“探索计划”项目，主题涉及皮质工作记忆、睡眠、自闭症、抑郁症、神经药理学和神经元再生等。作为国之重器，“多模态跨尺度生物医学成像设施”（国家十三五重大科技基础设施）的建设正在如火如荼地展开，预期于今年底投入试运行，2024年完成国家验收。依托此成像大设施，已启动“早鸟项目”，面向全国科技界滚动征集合作立项建议，计划在未来3-5年内发起生命科学包括脑科学领域的大科学计划，充分发挥“科技航母”的战略价值。大科学时代的生命科学特别需要新的工具，需要新型的研究平台。未来，更多新工具的开发以及新范式的探索，特别是大科学时代有组织科研的新范式，将为提升我国生物医学研究的整体水平，尤其是原始创新能力，实现高端生物医学仪器装备的“中国创造”提供强有力的战略支撑和保障。
个人简介
程和平院士长期致力于钙信号、线粒体生物医学领域的研究，以及高端生物医学仪器的自主创制。主要学术贡献为 ① 发现细胞钙信号基本单位—“钙火花”（Calcium Spark），原始论文曾被誉为100多年来十篇最杰出的心肌研究论文之一； ② 发现线粒体 “超氧炫”又称“线粒体炫”（Mitoflash），揭示其在能量代谢、学习记忆及衰老生物学中的信号功能；③率团队研发2.2克微型双光子显微镜，实现了在自由活动小鼠观察大脑神经元活动，开启脑科学研究的新范式。该项成果获“2017年中国科学十大进展”，并入选Nature Methods“2018年度方法”。此外，获国际心脏学会“Research Achievement Award”(2016），国家自然科学奖二等奖 （2017），何梁何利基金科学与技术进步奖（2020），北京大学2021年度国华杰出学者奖（2021），中国专利优秀奖（2022）等。